期刊文献+

托匹司他的合成工艺 被引量:5

Synthesis of Topiroxostat
原文传递
导出
摘要 在碘化亚铜和氰化锌存在下,异烟酸甲酯-N-氧化物与二甲胺基甲酰氯反应,生成化合物2-氰基异烟酸甲酯,经肼解得到2-氰基异烟肼,再与4-氰基吡啶缩合得到托匹司他粗品,与对甲苯磺酸一水合物反应成对甲苯磺酸盐,加入碳酸钾解离得标题化合物纯品,总收率41%。改进后的工艺原料易得,反应条件温和,工艺路线短,适合工业化生产。 Methyl isonicotinate-N-oxide reacted with dimethylcarbamyl chloride in the presence of cuprous iodide and zinc cyanide to give methyl 2-cyanopyridine-4-carboxylate, followed by hydrazinolysis to obtain 2-cyano isoniazide, then the latter was condensed with 4-cyanopyridine, followed by reaction with p-toluenesulfonic acid monohydrate and dissociation by potassium carbonate, the anti-hyperuricemia drug topiroxostat was prepared with an overall yield of 41%. This method started from cheap and easily obtained raw materials, with mild reaction conditions, short synthetic route and good potential for industrial application.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2016年第7期835-837,共3页 Chinese Journal of Pharmaceuticals
基金 国家自然科学基金项目(81473692) 江苏省前瞻性联合研究项目(BY2014005-01)
关键词 托匹司他 抗高尿血酸 抗痛风 合成 topiroxostat anti-hyperuricemia antigout drug synthesis
  • 相关文献

参考文献11

  • 1陈云,姚坤,陈冬寅,李飞.托比司他的合成工艺改进[J].合成化学,2015,23(8):770-773. 被引量:5
  • 2Hosya T, Ohno I, Nomura S, et al. Effect of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout [J]. Clin Exp Nephrol, 2014, 18 (6) : 876-884.
  • 3Sato T, Ashizawa N, Iwanaga T, et al. Design, synthesis, and pharmacological and pharmacokinetic evaluation of 3-phenyl-5-pyridy-l,2,4-triazole derivatives as xanthine oxidoreductase inhibitors [J]. Bioorg Med Chem Lett, 2009,19(1): 184-187.
  • 4Sato T, Ashizawa N, Matsumoto K, et al. Discovery of 3- (3-cyano-4-pyridyl) -5- (4-pyridy) -1,2,4-triazole, FYX- 051-axanthine oxidoreductase inhibitor for the treatment of hyperuricemia [J]. Bioorg Med Chem Lett, 2009, 19 (21): 6225-6229.
  • 5Kobayashi S, Ogura M, Hosoya T. Acute neutropenia associated with initiation of febuxostat therapy for hyperuricemia in patients with chronic kidney diease [Jl. J Clin Pharm Ther, 2013, 38 (3) : 258-261.
  • 6Ohya M, Shigematsu T. A new xanthine oxidase inhibitor: the uric acid reduction and additional effcacy in CKD patients [J]. Clin Exp Nephrol, 2014, 18 (6) : 835-836.
  • 7刘永贵,赵丽嘉,崔艳丽,贺星,沈雪砚,陈常青.抗高尿酸血症药物研究进展[J].现代药物与临床,2015,30(3):345-350. 被引量:56
  • 8株式会社富士药品.新的1,2,4三唑类化合物:中国,1531340[P],2005-01-05.
  • 9Huo ZB, Kosui T, Yamamoto Y. Zinc cyanide mediated direct acyanation of isonicotinic acid N-oxide.application to the synthesis of FYX-051, a xanthine oxidoreductase inhibitor [J]. Tetrahedron Lett, 2008, 49(28) : 4369-4371.
  • 10Huo ZB, Kosugi T, Yamamoto Y. The direct formation of 2-cyano-4-amidopyrine via x-cyanation of 4-amidopyridine N-oxide with dimethylcarbamoyl chloride and cheap potassium cyanide [J]. Acta Chim Slov, 2009, 56 (3) : 659- 663.

二级参考文献42

  • 1Khanna D, Fitzgerald J D, Khanna P P, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia [J]. Arthritis Care Res (Hoboken), 2012, 64(10): 1431- 1446.
  • 2Liu H, Zhang X M, Wang Y L, et al. Prevalence of hyperuricemia among Chinese adults: a national cross- sectional survey using multistage, stratified sampling [J]. JNephrol, 2014, 27(6): 653-658.
  • 3Zhu Y, Pandya B J, Choi H K. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007--2008 [J]. Am JMed, 2012, 125(7): 679-687.
  • 4Thomson reuters cortellis [DB/OL]. [2015-01-05]. https:// cortellis.thomsonreuterslifesciences.com.
  • 5Grewal H K, Martinez J R, Espinoza L R. Febuxostat: drug review and update [J]. Expert Opin Drug Metab Toxicol, 2014, 10(5): 747-758.
  • 6FDA. ULORIC (Febuxostat) prescribing information [OL]. [2012-11-10]. http://www.accessdata.fda.gov/drug satfda docs/label/2012/021856s0061bl.pdf.
  • 7Sugiyama A, Hashimoto H, Nakamura Y, et al. QT/QTc study conducted in Japanese adult healthy subjects: a novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation [J]. J Clin Pharmacol, 2014, 54(4): 446-452.
  • 8Hosoya T, Ohno I, Nomura S, et al. Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout [J]. Clin Exp Nephrol, 2014, 18(6): 876-884.
  • 9So A, Thorens B. Uric acid transport and disease [J]. J Clin Invest, 2010, 120(6): 1791-1799.
  • 10Bieber J D, Terkeltaub R A. Gout: on the brink of novel therapeutic options for an ancient disease [J]. Arthritis Rheum, 2004, 50(8): 2400-2014.

共引文献58

同被引文献22

引证文献5

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部